This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Ocugen (OCGN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ocugen (OCGN) delivered earnings and revenue surprises of +16.67% and -1.93%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Cooper Companies Q1 Earnings Likely to Reflect Seasonal Trends
by Zacks Equity Research
COO's fiscal first-quarter results are expected to follow seasonal trends, with a lighter start compared to the previous two reported quarters.
5 Biotech Breakthrough Stocks to Watch in 2025
by Kinjel Shah
It is a good idea to keep an eye on five biotech breakthrough stocks, MDMD, BEAM, ACLX, OCGN and INSM, as they may give great returns in the next 2-3 years
Ocugen (OCGN) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ocugen (OCGN) delivered earnings and revenue surprises of 0% and 5.33%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Ocugen to Begin Phase III Study on Eye Drug in Canada, Stock Up
by Zacks Equity Research
OCGN receives Health Canada's No Objection Letter to begin a phase III study on OCU400 for treating retinitis pigmentosa. Shares rise.
Is Ocugen (OCGN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Ocugen (OCGN) and Organon (OGN) have performed compared to their sector so far this year.
Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Atossa Genetics Inc. (ATOS) and Ocugen (OCGN) have performed compared to their sector so far this year.
Ocugen (OCGN) Skyrockets 209.6% Year to Date: Heres Why
by Zacks Equity Research
Ocugen's (OCGN) shares rise significantly in the year-to-date period on positive progress with its promising pipeline candidates.
Is Bicycle Therapeutics (BCYC) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Bicycle Therapeutics PLC Sponsored ADR (BCYC) and Ocugen (OCGN) have performed compared to their sector so far this year.
Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Ocugen (OCGN) is expected to provide updates regarding the developmental program of its lead candidate, OCU400, for two rare retinal diseases in the first-quarter earnings release.
Ocugen (OCGN) Up as DSMB Allows Cohort 2 Dosing in GA Study
by Zacks Equity Research
Ocugen (OCGN) stock gains as the DSMB for the phase I/II study of OCU410 approves the initiation of dosing with the medium dose of OCU410 in the dose-escalation phase of the GA study.
Ocugen Q2 Preview: Rebound Quarter Inbound?
by Derek Lewis
Ocugen shares have struggled over the last year, declining more than 60% in value and vastly underperforming the S&P 500.
Implied Volatility Surging for Ocugen (OCGN) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Ocugen (OCGN) stock based on the movements in the options market lately.
Ocugen (OCGN) Covaxin Studies Clinical Hold Lifted by FDA
by Zacks Equity Research
Ocugen (OCGN) gets respite after the FDA lifts the clinical hold on the company's phase II/III study, OCU-002, for Covaxin (BBV152).
Ocugen (OCGN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ocugen (OCGN) delivered earnings and revenue surprises of -280% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: SRRA Surges on GSK Buyout, HALO Offers Update & More
by Zacks Equity Research
Acquisition news from GlaxoSmithKline (GSK) and HALO are a few key highlights from the biotech sector during the past week.
Ocugen (OCGN) Stock Down as FDA Puts Hold on Covaxin Study
by Zacks Equity Research
Ocugen (OCGN) is conducting the OCU-002 study to support its BLA for the approval of Covaxin in the United States. The FDA places a clinical hold on this study.
The Zacks Analyst Blog Highlights Ocugen, Voyager Therapeutics, BioNTech, Regeneron and Gilead Sciences
by Zacks Equity Research
Ocugen, Voyager Therapeutics, BioNTech, Regeneron and Gilead Sciences are included in this blog.
Biotech Stock Roundup: OCGN Down on Update, VYGR Surges on Deal & Other Updates
by Zacks Equity Research
Regulatory and other details from Ocugen (OCGN) as well as Voyager (VYGR) are a few key highlights from the biotech sector during the past week.
Ocugen (OCGN) Down 23% With FDA Denial of COVID Vaccine EUA
by Zacks Equity Research
The FDA turns down an emergency use authorization request from Ocugen (OCGN) to use its COVID-19 vaccine Covaxin in pediatric population. Stock depreciates.
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
by Zacks Equity Research
Sector ETF report for XBI
Ocugen's (OCGN) COVID-19 Booster Effective Against Omicron
by Zacks Equity Research
Ocugen's (OCGN) India-based partner announces robust neutralizing antibody responses against Omicron and Delta variants, following the administration of the booster dose of COVID-19 vaccine, Covaxin.
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XBI
Ocugen (OCGN) Up on Bharat Biotech's Data in Pediatric Group
by Zacks Equity Research
Ocugen (OCGN) gains on Bharat Biotech's positive results from a study in the pediatric population.